EDT Matinas BioPharma (MTNB) files to sell 16.9M shares of common stock for holdersStay Ahead of the Market: Discover outperforming ...

Why it matters: The biopharma industry has largely been exempt from tariffs (except for 20% tariffs on imports to the US from China, implemented in March). The industry continues to brace for a ...

TORONTO (AP) — TORONTO (AP) — COSCIENS Biopharma Inc. (CSCI) on Wednesday reported a loss of $6.7 million in its fourth quarter. The Toronto-based company said it had a loss of $2.15 per share.

Morgan Stanley raised the firm’s price target on BioNTech (BNTX) to $140 from $139 and keeps an Overweight rating on the shares. The firm adjusted its large cap pharma and biotech models for ...

Ongoing streamlined efficiencies and cost cutting measures taken to refine operations and development pathway forward; Company ended the quarter with US$16.4 million in cash ...

YONGIN, South Korea, April 9, 2025 /PRNewswire/ -- GC Biopharma announced 09. Apr. 2025 that the Korean Ministry of Food and Drug Safety (MFDS) has approved its anthrax vaccine, BARYTHRAX, jointly ...

Aspire intends to request "fast track" approval on FDA application for its high-dose aspirin product HUMACAO, PR AND NEW YORK, NY / ACCESS Newswire / April 9, 2025 / Aspire Biopharma Holdings ...

As we previously discussed, beginning in 2022, a series of patent infringement lawsuits were filed against Moderna and collaborators Pfizer+BioNTech seeking damages based on their respective sales ...

About 16.5 billion euros ($18 billion) worth of biopharma investment in the EU-27 territories could be at risk within just the next three months, EFPIA said, citing a CEO survey conducted last ...

And Moderna isn’t the only company developing a flu+Covid combination shot. Pfizer and BioNTech have teamed up to develop an influenza and Covid-19 combination vaccine that uses mRNA technology ...

Backers, including BioNTech, have committed around one-third of the targeted IPO haul. China’s DualityBio filed to go public in Hong Kong last year but let that submission lapse. Having added ...

Clinical trials are being expanded globally by biopharma companies, including to emerging markets, which means professionals will have to be culturally sensitive and able to adapt quickly. There is ...